Attorney Docket No.: 020681-001710US

BIOLOGICALLY ACTIVE SUBSTANCES

ABSTRACT OF THE DISCLOSURE

The present invention provides liposomal L-carnitine formulations and methods for the treatment of intermittent claudication. The formulation is optimized with respect to L-carnitine transport through skin *in vitro*. Preferably, the formulation is a topical cream for the administration of the drug directly on the muscle group that is most affected by the poor local blood flow.

60081319 v1